Its a good_老虎社区_美港股上老虎

fongms
2021-10-08

Its a good start

Vaxart gained 7% in premarket trading<blockquote>Vaxart在盘前交易中上涨7%</blockquote>

(Oct 8) Vaxart, Inc shares are up 7% in premarket trading after publishing results in an animal mode

Vaxart gained 7% in premarket trading<blockquote>Vaxart在盘前交易中上涨7%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":821988958,"tweetId":"821988958","gmtCreate":1633686357602,"gmtModify":1633686357720,"author":{"id":3582495099582633,"idStr":"3582495099582633","authorId":3582495099582633,"authorIdStr":"3582495099582633","name":"fongms","avatar":"https://static.tigerbbs.com/af39086f575d7bf8ec2d34dcb560bb18","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Its a good start</p></body></html>","htmlText":"<html><head></head><body><p>Its a good start</p></body></html>","text":"Its a good start","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/821988958","repostId":1108043623,"repostType":4,"repost":{"id":"1108043623","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633682657,"share":"https://www.laohu8.com/m/news/1108043623?lang=zh_CN&edition=full","pubTime":"2021-10-08 16:44","market":"us","language":"en","title":"Vaxart gained 7% in premarket trading<blockquote>Vaxart在盘前交易中上涨7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108043623","media":"Tiger Newspress","summary":"(Oct 8) Vaxart, Inc shares are up 7% in premarket trading after publishing results in an animal mode","content":"<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> shares are&nbsp;up 7%&nbsp;in premarket trading after&nbsp;publishing results in an animal model that its COVID-19 vaccine pill can reduce airborne transmission of SARS-CoV-2.</p><p><blockquote>（10月8日）<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart公司</a></b>在公布动物模型结果表明其COVID-19疫苗可以减少新型冠状病毒病毒的空气传播后，该公司股价在盘前交易中上涨7%。</blockquote></p><p> Hamsters were vaccinated orally or intranasally with the vaccine candidate and then exposed to high levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared the virus in the nose and lungs quickly.</p><p><blockquote>仓鼠口服或鼻内接种候选疫苗，然后暴露于高水平的新冠肺炎病毒，以促进疫苗突破。接种疫苗的仓鼠很快清除了鼻子和肺部的病毒。</blockquote></p><p> But before clearing the infection, vaccinated hamsters were exposed to unvaccinated hamsters. The vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.</p><p><blockquote>但在清除感染之前，接种疫苗的仓鼠暴露于未接种疫苗的仓鼠。与未接种疫苗的仓鼠相比，接种疫苗的仓鼠感染的仓鼠更少，产生的临床症状也更轻。</blockquote></p><p> Results were published in&nbsp;BioRxiv, and have yet to be peer-reviewed.</p><p><blockquote>结果发表在BioRxiv上，尚未经过同行评审。</blockquote></p><p> Vaxart yesterday&nbsp;began recruitment in a phase 2 trial of the oral COVID vaccine.</p><p><blockquote>Vaxart昨天开始招募口服新冠疫苗的2期试验。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1ebf72c0d5d89ceb2daa800e4fd962dc\" tg-width=\"1176\" tg-height=\"569\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart gained 7% in premarket trading<blockquote>Vaxart在盘前交易中上涨7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart gained 7% in premarket trading<blockquote>Vaxart在盘前交易中上涨7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-08 16:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> shares are&nbsp;up 7%&nbsp;in premarket trading after&nbsp;publishing results in an animal model that its COVID-19 vaccine pill can reduce airborne transmission of SARS-CoV-2.</p><p><blockquote>（10月8日）<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart公司</a></b>在公布动物模型结果表明其COVID-19疫苗可以减少新型冠状病毒病毒的空气传播后，该公司股价在盘前交易中上涨7%。</blockquote></p><p> Hamsters were vaccinated orally or intranasally with the vaccine candidate and then exposed to high levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared the virus in the nose and lungs quickly.</p><p><blockquote>仓鼠口服或鼻内接种候选疫苗，然后暴露于高水平的新冠肺炎病毒，以促进疫苗突破。接种疫苗的仓鼠很快清除了鼻子和肺部的病毒。</blockquote></p><p> But before clearing the infection, vaccinated hamsters were exposed to unvaccinated hamsters. The vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.</p><p><blockquote>但在清除感染之前，接种疫苗的仓鼠暴露于未接种疫苗的仓鼠。与未接种疫苗的仓鼠相比，接种疫苗的仓鼠感染的仓鼠更少，产生的临床症状也更轻。</blockquote></p><p> Results were published in&nbsp;BioRxiv, and have yet to be peer-reviewed.</p><p><blockquote>结果发表在BioRxiv上，尚未经过同行评审。</blockquote></p><p> Vaxart yesterday&nbsp;began recruitment in a phase 2 trial of the oral COVID vaccine.</p><p><blockquote>Vaxart昨天开始招募口服新冠疫苗的2期试验。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1ebf72c0d5d89ceb2daa800e4fd962dc\" tg-width=\"1176\" tg-height=\"569\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108043623","content_text":"(Oct 8) Vaxart, Inc shares are up 7% in premarket trading after publishing results in an animal model that its COVID-19 vaccine pill can reduce airborne transmission of SARS-CoV-2.\nHamsters were vaccinated orally or intranasally with the vaccine candidate and then exposed to high levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared the virus in the nose and lungs quickly.\nBut before clearing the infection, vaccinated hamsters were exposed to unvaccinated hamsters. The vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.\nResults were published in BioRxiv, and have yet to be peer-reviewed.\nVaxart yesterday began recruitment in a phase 2 trial of the oral COVID vaccine.","news_type":1,"symbols_score_info":{"VXRT":0.9}},"isVote":1,"tweetType":1,"viewCount":1742,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":13,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}